Aeglea BioTherapeutics, Inc. (AGLE) insiders have most recently took part in a trading activity. On Dec 5, 2017 York Charles N Ii, CFO and VP bought 25,959 shares having total worth of $116,296 at the price of $4.48 per share, following the transaction a total of 34,787 shares owned by York Charles N Ii.
On the same day, Quinn Anthony G., Director bought 17,121 shares having total worth of $83,208 at the price of $4.86 per share, following the transaction a total of 27,121 shares owned by Quinn Anthony G..
Furthermore, over the past 12 months , the stock was traded 1 times by insiders. an employee of the company was the buyer in 1 instances.
Shares of Aeglea BioTherapeutics, Inc. (AGLE) traded down 6.69% on Dec 5, 2017, hitting $4.74. 76,239 shares of the company’s stock traded hands. Aeglea BioTherapeutics, Inc. has a 52 week low of $2.91 and a 52 week high of $8.11. The company’s market cap is $92 million.
Aeglea BioTherapeutics, Inc. (AGLE) last announced its earnings results on Nov 7, 2017. The company reported -0.48 earnings per share (EPS) for the quarter, higher than the consensus estimate of -0.55 by $0.07. The company had revenue of $1 million for the quarter, compared to the consensus estimate of $1 million. During the same quarter in the previous year, the company posted -0.47 earnings per share. The company’s revenue for the quarter was up 10% on a year-over-year basis.
|earnings per share||-0.48||-0.47||-0.33||-0.47||-7.10|
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018